On 25th March 2020, 62 organisations including patients, consumers, healthcare professionals, trade unions and public interest organisations published a letter to express our views on the importance of the role of public support to research and development during the current pandemic.
Since January, the European Commission and national governments have mobilised millions of Euros to promote research on COVID-19. We believe that an effective response requires that all these necessary medical tools are free of charge at the point of delivery, particularly for vulnerable populations.
We strongly recommend that the EU institutions and national governments incorporate collective, pro-public safeguards, such as transparency regarding public contributions, accessibility and affordability clauses and non-exclusive licences for exploitation of end-result products, in current and future funding calls and investments. These measures will eventually ensure the vaccines and treatments for the coronavirus reach those who need them and save numerous lives.
Download the full letter
– Read also the letter by the a cross-party group of 33 Members of the European Parliament to the European Commission to make COVID-19 tools affordable and available –
– Read also the letter by the a cross-party group of 33 Members of the European Parliament to the European Commission to make COVID-19 tools affordable and available –
Supporting organisations
- Access to Medicines Ireland
- Action against AIDS Germany
- AIDES, France
- AIDS Action Europe
- Aidsfonds
- Alliance for Cancer Prevention UK
- Altroconsumo, Italy
- Armenian Women For Health and Healthy Environment NGO
- Association of European Cancer Leagues (ECL), Access to Medicines Task Force
- AURORA Universities Network
- Austrian Institute for Health Technology Assessment (AIHTA)
- Center for international Environmental Law (CIEL)
- Commons Network (CN)
- Corporate Europe Observatory (CEO)
- CurbingCorruption
- Dying for a Cure
- Ecologistas en Acción, Spain
- EKPIZO, Greece
- Epilepsie France
- European Academy of Paediatrics
- European AIDS Treatment Group (EATG)
- European Alliance for Responsible R&D and Affordable Medicines
- European Association of Hospital Pharmacists (EAHP)
- European Federation of Public Service Unions (EPSU)
- European Institute of Women’s Health
- European Public Health Alliance (EPHA)
- France Assos Santé, France
- Global Health Advocates (GHA)
- Groupe sida Genève, Switzerland
- Grupo de Ativistas em Tratamentos (GAT), Portugal
- Health Action International (HAI)
- International Association of Mutual Benefit Societies (AIM)
- Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Germany
- Istituto di Ricerche Farmacologiche Mario Negri, Italy
- Just Treatment
- La Ligue contre le cancer, FRANCE
- Médecins du Monde
- MSF Access Campaign
- NoGracias, Spain
- Observatoire de la transparence dans les politiques du médicament (OTMeds)
- Organización de Consumidores y Usuarios (OCU), Spain
- Pesticide Action Network (PAN) Europe
- Pharmaceutical Accountability Foundation
- PRAKSIS, Greece
- Prescrire
- Public Eye, Switzerland
- Réseau DES, France
- Réseau Environnement Santé
- Romanian Association Against AIDS (ARAS)
- Salud por Derecho, Spain
- Sciences Citoyennes
- SOMO – Centre for Research on Multinational Corporations
- Standing Committee of European Doctors (CPME)
- STOPAIDS
- T1International
- Test Aankoop/Test Achats, Belgium
- Transnational Institute
- Transparency International Health Initiative
- TranspariMED
- UFC-Que Choisir, France
- Universities Allied for Essential Medicines (UAEM) Europe
- Wemos